ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

BeOne Medicines and AbbVie side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

BeOne MedicinesAbbVie
studies on the registry1952,251
open to participants now51133
phase 3 studies under way1974
reach primary completion within a year2390
programswith a study of their own in two years2470+8 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseBeOne MedicinesAbbVie
Phase 167%

AbbVie: 28 of its 70 programs at phase 1

  1. Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31phase 1
  2. surzetoclaxphase 1
  3. BTK Degrader ABBV-101phase 1
  4. ABBV-1162phase 1
  5. ABBV-1451phase 1

and 23 more — sign in to see them all

40%
Phase 2

BeOne Medicines: 1 of its 24 programs at phase 2

  1. BGB-45035phase 2
4%

AbbVie: 20 of its 70 programs at phase 2

  1. ABBV-295phase 2
  2. zumilokibartphase 2
  3. ABBV-932phase 2
  4. trosunilimabphase 2
  5. ABBV-701phase 2

and 15 more — sign in to see them all

29%
Phase 3

BeOne Medicines: 6 of its 24 programs at phase 3

  1. sonrotoclaxphase 3
  2. tislelizumabphase 3
  3. tacabrutidegphase 3
  4. Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033phase 3
  5. CDK4 Inhibitor BGB-43395phase 3

and 1 more — sign in to see them all

25%

AbbVie: 16 of its 70 programs at phase 3

  1. telisotuzumab adizutecanphase 3
  2. etentamigphase 3
  3. lutikizumabphase 3
  4. mirvetuximab soravtansinephase 3
  5. turmetabart adizutecanphase 3

and 11 more — sign in to see them all

23%
Approved, new studies

BeOne Medicines: 1 of its 24 programs at approved, new studies

  1. zanubrutinibapproved, new study
4%

AbbVie: 6 of its 70 programs at approved, new studies

  1. upadacitinibapproved, new study
  2. risankizumabapproved, new study
  3. venetoclaxapproved, new study
  4. botulinum toxin type Aapproved, new study
  5. atogepantapproved, new study

and 1 more — sign in to see them all

9%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
BeOne Medicines10 readouts · 1 phase 3

BeOne Medicines, Nov ’26: 4 programs whose next study reaches primary completion

  1. sonrotoclaxphase 3 · Nov 0 · NCT04973605
  2. tislelizumabphase 3 · Nov 0 · NCT03736889
  3. CDK4 Inhibitor BGB-43395phase 3 · Nov 22 · NCT07820891
  4. tacabrutidegphase 3 · Nov 30 · NCT07005713

BeOne Medicines, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zanubrutinibapproved, new study · Dec 31 · NCT04170283
··

BeOne Medicines, Mar ’27: 1 program whose next study reaches primary completion

  1. Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033phase 3 · Mar 31 · NCT06427941
···

BeOne Medicines, Jul ’27: 2 programs whose next study reaches primary completion

  1. PRMT5 Inhibitor BGB-58067phase 1 · Jul 1 · NCT07712640
  2. Bcl-2 Inhibitor BGB-21447phase 1 · Jul 30 · NCT06756932
·

BeOne Medicines, Sep ’27: 1 program whose next study reaches primary completion

  1. Anti-B7-H4 Antibody Drug Conjugate BG-C9074phase 3 · Sep 28 · NCT06233942

BeOne Medicines, Oct ’27: 1 program whose next study reaches primary completion

  1. BON-107phase 1 · Oct 11 · NCT07934069
AbbVie34 readouts · 5 phase 3

AbbVie, Nov ’26: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-701phase 2 · Nov 0 · NCT06895343
  2. ABBV-932phase 2 · Nov 0 · NCT06846320
  3. mirvetuximab soravtansinephase 3 · Nov 0 · NCT05456685
  4. upadacitinibapproved, new study · Nov 0 · NCT06389136
  5. venetoclaxapproved, new study · Nov 0 · NCT04895436

and 1 more — sign in to see them all

AbbVie, Dec ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-295phase 2 · Dec 0 · NCT07514260
  2. emraclidinephase 2 · Dec 0 · NCT07219030
  3. lutikizumabphase 3 · Dec 0 · NCT06468228
  4. telisotuzumab adizutecanphase 3 · Dec 0 · NCT06107413

AbbVie, Jan ’27: 1 program whose next study reaches primary completion

  1. risankizumabapproved, new study · Jan 0 · NCT07466550

AbbVie, Feb ’27: 9 programs whose next study reaches primary completion

  1. [11C]ABBV-112iearly phase 1 · Feb 0 · NCT07933497
  2. ABBV-859phase 1 · Feb 0 · NCT07736638
  3. Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31phase 1 · Feb 0 · NCT05512390
  4. etentamigphase 3 · Feb 0 · NCT06223516
  5. MEDI0618phase 2 · Feb 0 · NCT06602479

and 4 more — sign in to see them all

·

AbbVie, Apr ’27: 1 program whose next study reaches primary completion

  1. ABBV-1451phase 1 · Apr 0 · NCT07570147

AbbVie, May ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-1162phase 1 · May 0 · NCT07832708
  2. ABBV-243phase 1 · May 0 · NCT07306754
  3. ABBV-7828phase 1 · May 0 · NCT07856706
  4. Anti-PSMA/STEAP1 Antibody-drug Conjugate ABBV-969phase 1 · May 0 · NCT06318273
  5. trosunilimabphase 2 · May 0 · NCT07925983

and 1 more — sign in to see them all

AbbVie, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. botulinum toxin type Aapproved, new study · Jun 0 · NCT07794891

AbbVie, Jul ’27: 4 programs whose next study reaches primary completion

  1. ABBV-1606phase 1 · Jul 0 · NCT07935564
  2. azirkitugphase 1 · Jul 0 · NCT05005403
  3. surzetoclaxphase 2 · Jul 0 · NCT06291220
  4. surzetoclaxphase 1 · Jul 0 · NCT06291220

AbbVie, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. vedolizumabphase 3 · Aug 0 · NCT06880744

AbbVie, Sep ’27: 1 program whose next study reaches primary completion

  1. icalcaprantphase 2 · Sep 0 · NCT07276997
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

BeOne Medicines

New programs 6

  • BON-C1393phase 1 · first study · Oct 23
  • BON-107phase 1 · first study · Oct 22
  • BG-92505phase 1 · first study · Oct 21
  • BON-106phase 1 · first study · Oct 19 · Neoplasm Metastasis
  • BG-T0920phase 1 · first study · Oct 15 · Lymphoma, Large B-Cell, Diffuse
  • BG-T0050phase 1 · first study · Oct 12 · Lymphoma, Large B-Cell, Diffuse

Reached a new phase 2

Study stopped 0

None

Primary completion later 2

AbbVie

New programs 5

Reached a new phase 1

  • ABBV-722phase 3 · Oct 23 · Scleroderma, Systemic

Study stopped 0

None

Primary completion later 10

Where they overlap

Conditions where at least two of them have programs: 12 in all. A program counts in each condition its studies name most.

ConditionBeOne MedicinesAbbVie
Multiple Myelomaboth · compare here

BeOne Medicines in Multiple Myeloma: 1 program

  1. sonrotoclaxphase 3

Their studies: BeOne Medicines’ studies of Multiple Myeloma in search

Arthritis, Rheumatoidboth · compare here

BeOne Medicines in Arthritis, Rheumatoid: 1 program

  1. BGB-45035phase 2

Their studies: BeOne Medicines’ studies of Arthritis, Rheumatoid in search

AbbVie in Arthritis, Rheumatoid: 5 programs

  1. lutikizumabphase 3
  2. ABBV-722phase 3
  3. ravagalimabphase 2
  4. CPTX2309phase 1
  5. upadacitinibapproved, new study

Their studies: AbbVie’s studies of Arthritis, Rheumatoid in search

Leukemia, Lymphocytic, Chronic, B-Cellboth · compare here

BeOne Medicines in Leukemia, Lymphocytic, Chronic, B-Cell: 3 programs

  1. sonrotoclaxphase 3
  2. tacabrutidegphase 3
  3. zanubrutinibapproved, new study

Their studies: BeOne Medicines’ studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

AbbVie in Leukemia, Lymphocytic, Chronic, B-Cell: 3 programs

  1. surzetoclaxphase 2
  2. surzetoclaxphase 1
  3. venetoclaxapproved, new study

Their studies: AbbVie’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Breast Neoplasmsboth · compare here

AbbVie in Breast Neoplasms: 2 programs

  1. trifluridine tipiracil drug combinationphase 3
  2. RC148no phase

Their studies: AbbVie’s studies of Breast Neoplasms in search

Carcinoma, Non-Small-Cell Lungboth · compare here

BeOne Medicines in Carcinoma, Non-Small-Cell Lung: 1 program

  1. tislelizumabphase 3

Their studies: BeOne Medicines’ studies of Carcinoma, Non-Small-Cell Lung in search

AbbVie in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. telisotuzumab adizutecanphase 3
  2. ABBV-1480phase 3
  3. azirkitugphase 1
  4. RC148no phase

Their studies: AbbVie’s studies of Carcinoma, Non-Small-Cell Lung in search

Lymphoma, Large B-Cell, Diffuseboth · compare here

BeOne Medicines in Lymphoma, Large B-Cell, Diffuse: 3 programs

  1. BG-T0050phase 1
  2. BG-T0920phase 1
  3. zanubrutinibapproved, new study

Their studies: BeOne Medicines’ studies of Lymphoma, Large B-Cell, Diffuse in search

Carcinoma, Hepatocellularboth · compare here

BeOne Medicines in Carcinoma, Hepatocellular: 2 programs

  1. tislelizumabphase 3
  2. Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033phase 3

Their studies: BeOne Medicines’ studies of Carcinoma, Hepatocellular in search

AbbVie in Carcinoma, Hepatocellular: 1 program

  1. telisotuzumab adizutecanphase 3

Their studies: AbbVie’s studies of Carcinoma, Hepatocellular in search

Leukemia, Myeloid, Acuteboth · compare here

BeOne Medicines in Leukemia, Myeloid, Acute: 1 program

  1. sonrotoclaxphase 3

Their studies: BeOne Medicines’ studies of Leukemia, Myeloid, Acute in search

AbbVie in Leukemia, Myeloid, Acute: 2 programs

  1. pivekimab sunirinephase 3
  2. venetoclaxapproved, new study

Their studies: AbbVie’s studies of Leukemia, Myeloid, Acute in search

Lymphoma, Mantle-Cellboth · compare here

BeOne Medicines in Lymphoma, Mantle-Cell: 2 programs

  1. sonrotoclaxphase 3
  2. zanubrutinibapproved, new study

Their studies: BeOne Medicines’ studies of Lymphoma, Mantle-Cell in search

AbbVie in Lymphoma, Mantle-Cell: 1 program

  1. venetoclaxapproved, new study

Their studies: AbbVie’s studies of Lymphoma, Mantle-Cell in search

Lymphoma, Non-Hodgkinboth · compare here

BeOne Medicines in Lymphoma, Non-Hodgkin: 2 programs

  1. tacabrutidegphase 3
  2. Bcl-2 Inhibitor BGB-21447phase 1

Their studies: BeOne Medicines’ studies of Lymphoma, Non-Hodgkin in search

AbbVie in Lymphoma, Non-Hodgkin: 1 program

  1. venetoclaxapproved, new study

Their studies: AbbVie’s studies of Lymphoma, Non-Hodgkin in search

Carcinoma, Ovarian Epithelialboth · compare here

BeOne Medicines in Carcinoma, Ovarian Epithelial: 1 program

  1. Anti-B7-H4 Antibody Drug Conjugate BG-C9074phase 3

Their studies: BeOne Medicines’ studies of Carcinoma, Ovarian Epithelial in search

AbbVie in Carcinoma, Ovarian Epithelial: 1 program

  1. mirvetuximab soravtansinephase 3

Their studies: AbbVie’s studies of Carcinoma, Ovarian Epithelial in search

Stomach Neoplasmsboth · compare here

BeOne Medicines in Stomach Neoplasms: 1 program

  1. tislelizumabphase 3

Their studies: BeOne Medicines’ studies of Stomach Neoplasms in search

AbbVie in Stomach Neoplasms: 1 program

  1. trifluridine tipiracil drug combinationphase 3

Their studies: AbbVie’s studies of Stomach Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: BeOne Medicines 12 of 24 · AbbVie 54 of 70 programs (25 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AbbVie: 8).